TScan Therapeutics Email Format
Biotechnology ResearchMassachusetts, United States51-200 Employees
Based in Waltham, Massachusetts, TScan Therapeutics is a biotechnology company focused on developing T cell receptor-engineered T cell therapies for patients. Founded in 2018, it operates an integrated platform that aims to rapidly identify T cell receptors and their targets for engineered T cells. The approach is designed to be versatile, with potential applications across cancer as well as autoimmune and infectious diseases. Its primary market includes biopharmaceutical developers seeking to accelerate the discovery of TCRs and corresponding targets to advance TCR-T therapies. In 2026, the company announced a collaboration with Cellares to evaluate automated manufacturing of a TCR-T therapy candidate for acute myeloid leukemia.